

ATTCT and ATTCC repeat expansions in the ATXN10 gene affect disease penetrance of spinocerebellar ataxia type 10

C. Alejandra Morato Torres,^{1,8} Faria Zafar,^{1,8} Yu-Chih Tsai,² Jocelyn Palafox Vazquez,¹ Michael D. Gallagher,³ Ian McLaughlin,² Karl Hong,³ Jill Lai,³ Joyce Lee,³ Amanda Chirino-Perez,⁴ Angel Omar Romero-Molina,⁴ Francisco Torres,⁵ Juan Fernandez-Ruiz,⁴ Tetsuo Ashizawa,⁶ Janet Ziegler,² Francisco Javier Jiménez Gil,⁷ and Birgitt Schüle^{1,9,*}

Summary

Spinocerebellar ataxia type 10 (SCA10) is an autosomal-dominant disorder caused by an expanded pentanucleotide repeat in the *ATXN10* gene. This repeat expansion, when fully penetrant, has a size of 850–4,500 repeats. It has been shown that the repeat composition can be a modifier of disease, e.g., seizures. Here, we describe a Mexican kindred in which we identified both pure (ATTCT)_n and mixed (ATTCT)_n-(ATTCC)_n expansions in the same family. We used amplification-free targeted sequencing and optical genome mapping to decipher the composition of these repeat expansions. We found a considerable degree of mosaicism of the repeat expansion. This mosaicism was confirmed in skin fibroblasts from individuals with *ATXN10* expansions with RNAScope *in situ* hybridization. All affected family members with the mixed *ATXN10* repeat expansion showed typical clinical signs of spinocerebellar ataxia and epilepsy. In contrast, individuals with the pure *ATXN10* expansion present with Parkinson's disease or are unaffected, even in individuals more than 20 years older than the average age at onset for SCA10. Our findings suggest that the pure (ATTCT)_n expansion is non-pathogenic, while repeat interruptions, e.g., (ATTCC)_n, are necessary to cause SCA10. This mechanism has been recently described for several other repeat expansions including SCA31 (*BEAN1*), SCA37 (*DAB1*), and three loci for benign adult familial myoclonic epilepsy BAFME (*SAMD12*, *TNRC6A*, *RAPGEF2*). Therefore, long-read sequencing and optical genome mapping of the entire genomic structure of repeat expansions are critical for clinical practice and genetic counseling, as variations in the repeat can affect disease penetrance, symptoms, and disease trajectory.

Introduction

Complex pentanucleotide repeats within intron 9 of the *ATAXIN 10* (*ATXN10* [MIM:611150]) gene cause spinocerebellar ataxia type 10 (SCA10 [MIM:603516]), a rare autosomal-dominant disease that is most prevalent in Middle and South America.¹ These repeats can comprise several thousand when clinically fully penetrant.^{2,3} The normal ATTCT repeat allele size is 10–32 repeats, whereas intermediate alleles with reduced penetrance contain 280–850 repeats. Complete penetrance of SCA10 typically has between 850 and 4,500 repeats.^{2,3}

Clinically, SCA10 presents with a symptom complex of spinocerebellar ataxia, gait ataxia, dysarthria, nystagmus, epilepsy, cognitive decline, and non-motor symptoms.⁴ These symptoms affect quality of life measures, particularly “physical functioning” and “physical role.”⁵ In addition, non-motor symptoms include increased fatigue (32% of SCA10 versus 3.6% control group [*p* = 0.005]),⁶ changes in rapid eye movement (REM) sleep patterns

(more extended REM periods and more REM arousals), and a higher respiratory disturbance index (RDI).⁷ Assessment of changes in the sense of smell or cancer risk shows no significant differences compared with controls.^{8,9} High-resolution magnetic resonance imaging (MRI) in 18 patients with SCA10 revealed white matter atrophy starting in the posterior/floculonodular cerebellum and gray matter degeneration in the cerebellum and brainstem thalamus. The putamen was more pronounced in patients with severe disease. Additionally, patients with SCA10 with epilepsy had lower gray matter intensity in the thalamus and a loss of integrity of the white matter in lobule VI of the cerebellum.¹⁰

Diagnostically, genetic sequencing analysis of *ATXN10* expansion length has been challenging due to its repetitive nature. Furthermore, southern blotting has inherent problems with accurate sizing and considerable variability between clinical diagnostic laboratories. PCR for repetitive regions shows reduced amplification efficiency, allele bias, allele dropout,¹¹ and replication slippage effects.¹² Therefore, the somatic variability of repeat

¹Department Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA; ²Pacific Biosciences of California, Inc., Menlo Park, CA 94025, USA; ³Bionano Genomics, San Diego, CA 92121, USA; ⁴Laboratorio de Neuropsicología, Departamento de Fisiología, Facultad de Medicina, Universidad Nacional Autónoma de México, CDMX 04510, Mexico; ⁵Southern California Permanente Medical Group, Oxnard, CA 93036, USA; ⁶Department Neurology, Houston Methodist Research Institute, Houston, TX 77030, USA; ⁷Hospital San Javier S.A. de C.V., Guadalajara, Jalisco 44670, Mexico

⁸These authors contributed equally

⁹Lead contact

*Correspondence: bschuele@stanford.edu

<https://doi.org/10.1016/j.xhgg.2022.100137>.

© 2022 The Authors. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).






Figure 1. ATXN10 pedigree of Mexican family

Roman numerals indicate generations to the left of each pedigree. Circles indicate female gender, squares indicate male gender, triangle indicates miscarriage, black symbols indicate affected individuals with SCA10, the red symbol indicates Parkinson's disease, half black symbol indicates SCA10 affected by medical history, and dots in the middle of the symbol mean individuals with *ATXN10* repeat expansion but unaffected. Black dots indicate individual with interrupted repeat expansion, and the red dot indicates pure ATTCT repeat expansion. The age range in generation III is 57–74 years and in generation IV is 19–52 years. All individuals in the III and IV generations have been clinically evaluated by F.J.J.G. or J.F.-R. except III.1 (stillbirth) and III.5. In this study, we had DNA available for individuals labeled with an asterisk (*) for amplification-free sequencing, and individuals labeled with a hash symbol (#) had DNA with high molecular weight quality for Saphyr optical genome mapping. For details of disease, age at disease onset as well as *ATXN10* genotypes are listed in Table 1.

elements is challenging to assess because of replication errors.

Besides the repeat length, the *ATXN10* pentanucleotide repeat can have variable genomic structure configurations: pure (ATTCT)*n* repeats and mixed (ATTCT)*n*-(ATTCC)*n* or (ATTCT)*n*-(ATCCT)*n*-(ATCCC)*n* repeats with additional interruptions of hepta- or octanucleotide repeats.³ However, current clinical genetic diagnostics cannot determine the *ATXN10* pentanucleotide repeat composition. More recent developments of repeat-prime PCR with high-resolution pulse-field capillary electrophoresis analysis¹³ and long-range sequencing³ in the research setting allow for refinement of *ATXN10* repeat composition.

It is very likely that the genomic composition of the *ATXN10* repeat expansion leads to different clinical phenotypes and pathophysiological changes in patients and may influence the pathogenicity and penetrance of the expanded repeat allele. For example, epileptic seizures in SCA10 can present as complex partials with occasional secondary generalizations, greatly influencing morbidity and mortality of the disease. The ATCCT interruption of the ATTCT repeat expansion shows a higher risk (6.3-fold) of developing seizures.¹⁴

Here, we performed amplification-free targeted sequencing (Pacific Biosciences) and optical genome mapping (Bionano Genomics) in three generations of a large family from Mexico with SCA10 to assess repeat size and repeat composition in affected and unaffected relatives. We characterized the somatic variability of the repeat composition in skin fibroblasts from individuals with *ATXN10* expansions. We show that the variable

expansions translated into variable size and number of RNA foci detected by RNAScope *in situ* hybridization.

Subjects and methods

Ethics statement

This study was approved by the ethics committee of Stanford University School of Medicine (Stanford IRB-48895). All participants provided written informed consent.

Clinical assessment

We previously reported on this family and have expanded the recruitment of family members to include relatives of the third generation.¹⁵ The pedigree is depicted in Figure 1. Cases histories for family members that carry repeat expansions but have not been previously reported are described in the supplemental information.

DNA isolation

DNA from saliva was extracted with Oragene-500 kit according to manufacturer's instructions. For optical genome mapping, we isolated ultra-high molecular weight (UHMW) genomic DNA from blood using the Bionano Prep SP Blood & Cell Culture DNA Isolation Kit (Bionano, cat. no. 80030).

Short tandem repeat (STR) fragment analysis for identity testing

For identity testing, we used the AmpFISTR Identifier Plus PCR Amplification Kit (Thermo Fisher Scientific, cat. no. 4427368) according to the manufacturer's instructions. The kit uses a five-dye fluorescent system, and the inclusion of non-nucleotide linkers allows for simultaneous amplification and efficient separation of 15

STR loci. Electropherograms of the fragments were analyzed using NCBI's OSIRIS 2.13.1 program (Table S1).

Amplification-free targeted sequencing

DNA samples were further purified with AMPure PB beads (PacBio, cat. no. 100-265-900) before processing, and quality control (QC) on DNA samples was performed using Agilent Femto pulse analysis. Using a modified PacBio amplification-free targeted sequencing method protocol, we started with five μ g input DNA for each sample and sequenced with a 20 h PacBio Sequel System/Sequencing run. More specifically, non-sequencable single-molecule real-time bell (SMRTbell) libraries were generated from native genomic DNA digested with the restriction enzyme EcoRI-HF and a short hairpin adapter with barcode sequences. These short hairpin adapters do not contain sequencing primer complementary sequences to prevent sequencing reaction initiation. We then introduced double-strand breaks to the SMRTbell templates that contained our region of interest using Cas9 and a guide RNA (*ATXN10*-5'-AUACAAG GAUCAGAAUCCC-3') designed to be complementary to a sequence adjacent to the region of interest.¹⁶ The SMRTbell library hairpin adapter was subsequently ligated to the digested templates to form asymmetric SMRTbell libraries that allow sequencing primers to anneal with the second hairpin adapter introduced after Cas9 enzyme digestion. The library was digested with an enzyme cocktail containing exonuclease III, exonuclease VII, and four restriction enzymes (BssSøI, BlnI, SpeI, and KpnI) to remove a large portion of the non-target DNA fragments from the final library. The selected restriction enzymes are not predicted to cut inside the DNA fragments with the *ATXN10* repeat expansion region. The final sequencing libraries were treated with trypsin and purified with AMPure PB beads before primer annealing, polymerase binding, and sequencing.

Sequencing data were first processed with PacBio SMRT analysis tool v.5.0 to identify hairpin adapters, demultiplex reads from different samples, and generate circular consensus sequencing (CCS) reads with predicted read quality above a Q20 Phred quality score. CCS reads from each sample were mapped against human reference sequence hg19, and *ATXN10* repeat sequences from on-target sequencing reads were extracted from reads mapped through reference coordinates chr22:46,191,235–46,191,304. Repeat sequence length distributions and waterfall plots depicting repeat sequence variations (Figures 2 and S1) were generated using either custom software scripts or repeat analysis tools available on the GitHub website (<https://github.com/PacificBiosciences/apps-scripts/tree/master/RepeatAnalysisTools>) following the recommended data analysis workflow on the PacBio website (<https://www.pacb.com/wp-content/uploads/Analysis-Procedure-No-Amp-Data-Preparation-and-Repeat-Analysis.pdf>).

Optical genome mapping and analysis with the Saphyr system

Briefly, 750 ng UHMW (>100 kb) genomic DNA was labeled with DLE-1 enzyme (Bionano Genomics) and the DNA backbone was counterstained according to Bionano Prep Direct Label and Stain protocol (document number: 30206, document revision: F) before loading on to the Bionano Chip. Loading of the chip and running of the Bionano Genomics Saphyr System were performed according to the Saphyr System User Guide (<https://bionanogenomics.com/support-page/saphyr-system/>). We used the Bionano *de novo* assembly and variant annotation pipelines to generate whole-genome assembly contigs, which span whole-chromosome arms and identify variants down to 500 bp. For single-

variant (SV) detection, the consensus genome maps were aligned to reference (hg38). After running the *de novo* assembly pipeline using Solve v.1.7 and visualizing with Access v.3.7, we identified somatic rearrangements by selecting novel SVs to the Bionano control sample database (zero population frequency [out of 204 samples], thus potentially somatic mutations) and SVs with strong molecule support (remove false positives due to assembly errors). Somatic variability was investigated in the *de novo* assemblies by aligning single-molecule data to each map containing the repeat expansion. These molecules were both manually visualized and subsequently plotted by bp distance between the two labels of interest that encompass the repeat expansion to show the presence/absence of somatic mosaicism (Figure 3).

In situ hybridization with RNAScope

Human skin fibroblasts were derived from 4 mm skin biopsies, maintained, and banked as we previously described.¹⁷ For fibroblast-cell culture, 8-well chamber slides (Nunc Lab-Tek chamber slide, Sigma, cat. no. C7182) were coated with 0.1% gelatin for 15 min. 60,000 cells were seeded in each chamber and incubated overnight. The next day, slides were fixed with 10% neutral buffered formalin for 15 min and dehydrated by gradually increasing ethanol concentrations (50%, 70%, 100%).

In situ hybridization was performed according to the manufacturer's instructions using the RNAScope multiplex fluorescent assay v.2 kit. In brief, slides were treated with RNAScope hydrogen peroxide (part number 322335) for 10 min at room temperature, followed by a protease III incubation (10 min, room temperature). Probe (Hs-*ATXN10*-ATTCT-C1, ACDBio, part ID 1001381), positive control (part number, 320861), and negative control (ACD, part number 320871) hybridizations were performed in an HyBEZ oven (ACD, HyBEZ II Hybridization System, part number 321710) at 40°C for 2 h. Slides were washed and subjected to three steps of amplification: AMP1 (30 min, 40°C), AMP2 (40°C), and AMP3 (15 min, 40°C). Then, slides were incubated with RNAScope HRP-C1 for 15 min at 40°C, followed by a washing cycle and incubation with TSA Plus fluorophore (1:600) for 30 min at 40°C. Lastly, slides were blocked with a horseradish peroxidase (HRP) blocker for 15 min at 40°C and counterstained with a nuclear marker (DAPI). RNAScope slides were covered with Prolong Gold Antifade reagent (Invitrogen, P36930) and a 22 \times 50 mm coverslip for imaging. Imaging was performed on an ImageXpress Pico (Molecular Devices) and analyzed with CellReporterXpress Image Acquisition software (Molecular devices v.2.6.130), and RNA foci were analyzed using the "pits and vesicles" software. Statistical analysis of RNA foci counts was performed in GraphPad Prism using a one-way ANOVA ($\alpha \leq 0.05$) and a Brown-Forsythe and Welch test (95% confidence interval [CI]).

Results

We describe a four-generation Mexican family with an autosomal-dominant inheritance of an *ATXN10* repeat expansion. We recently reported on this family and, interestingly, identified an individual of this family affected with typical L-dopa-responsive Parkinson's disease and a pure (ATTCT)_n repeat expansion¹⁵ (Figure 1). Here, we expanded our genetic studies and included additional techniques of optical genome mapping and RNAScope *in situ* hybridization to understand the repeat size, genomic structure, and somatic variability in order to




Figure 2. Waterfall plots for amplification-free targeted sequencing of individuals with pure $(ATTCT)_n$ expansions and mixed $(ATTCT)_n-(ATTCC)_n$ expansions

Examples of pure and mixed repeat expansion from different family members in generations III and IV showing repeat inter- and intra-individual variability. A row of dots represents repeat sequences in each sequencing read in this plot. Dots with different colors represent a different unit of repeat sequence context. Dark gray: ATTCT; gold: ATTCC; light blue: ATTCT; green: ATTCT. Circular consensus sequencing (CCS) reads are consensus sequences resulting from alignment between subreads taken from a single long-read sequence. Generating a CCS read does not include or require alignment against a reference sequence but does require at least two full-pass subreads from the insert. We detected rare hexanucleotide repeats (ATTCT and ATTCT) in the circular consensus reads, which were seen in several family members in a consistent pattern. For additional details, see [Figure S1](#).




Figure 3. Visualization of optical genome mapping for four individuals with *ATXN10* repeat expansions as molecule distance graphs and histograms

The top half of individual optical genome maps represent unexpanded molecules, and the bottom part shows expanded alleles. The green bar represents the reference allele (hg38) with marks at all locations of the sequence motif (vertical lines), which is recognized by the Bionano optical genome mapping enzyme (e.g., DLE-1, Nt.BspQI, Nb.BssSI), which occurs every 5 kbp on average. Genome maps (blue bars) are produced from images of labeled DNA molecules >150 kbp for the target DNA. We measured expanded alleles between reference label IDs 5,045 and 5,048 (*ATXN10* cytogenetic location: 22q13.31, genomic coordinates [GRCh38]: 22:45,671,834–45,845,307). We measured the distance between labels 5,045 (green box) and 5,048 (red box) and calculated the expansion size. Histograms show the distribution of normal and expanded alleles for each sample. Shown are mean distance between labels, standard deviation (SD), and proportion of molecules in allele.

gain additional insight into the genetic mechanisms of the *ATXN10* repeat expansion, clinical presentation, and disease trajectory.

Individuals with pure (ATTCT)_n repeat expansion show reduced clinical penetrance for SCA10

We examined 22 family members from generations III (7 individuals) and IV (15 individuals) of the family (Figure 1) and collected blood, saliva, and skin biopsies from individuals who consented to the study protocol. Sixteen individuals had an *ATXN10* repeat expansion (rs60726084, 7 in generation III, 9 in generation IV). We found six relatives in generation IV who had normal *ATXN10* repeat expansions. Of the 16 individuals with expanded *ATXN10* repeats, ten presented with the mixed (ATTCT)_n-(ATTCC)_n repeat expansion (Figure 1, black symbols), and six showed the pure (ATTCT)_n repeat expansion (Figure 1, red symbols). Of the ten cases with a mixed repeat expansion, five were affected with typical SCA10, with an average age at onset of 41.6 years (range 35–48 years, III.2, III.3, III.7, III.9, IV.1), and three of the five had seizures (III.2, III.3, III.7). The five unaffected individuals of the mixed repeat could be pre-symptomatic at ages 20, 33, 39, 40, and 51. Further longitudinal clinical follow up will be necessary.

Of the six relatives with pure (ATTCT)_n expansion, one developed Parkinson's disease at age 38, while the other five were unaffected. Two of them have passed the average age at onset in this family by over 20 years (age at last visit:

65 and 70 years), while the other three individuals with the pure (ATTCT)_n repeat expansion could still be pre-symptomatic at ages 18, 38, and 44 years. None of the individuals with the pure (ATTCT)_n expansion presented with medical history or symptoms compatible with the diagnosis of SCA10 (supplemental information, case history III.6).

Inheritance of pure and mixed *ATXN10* repeat expansion

We observed two structurally very different repeat expansions in this family. One *ATXN10* repeat presented as a pure (ATTCT)_n expansion and the other as a mixed (ATTCT)_n-(ATTCC)_n expansion. There is no clear explanation of how a repeat can mutate from one complex repeat pattern to another in one generation, e.g., from generation II to III. It is also unusual that all siblings in generation III carry an extended *ATXN10* allele. Usually, in an autosomal-dominant inheritance pattern, one would expect 50% of the offspring to have an *ATXN10* repeat expansion and 50% the normal allele. To exclude non-paternity, we tested 15 microsatellite markers, and all siblings in generation III tested showed matching alleles (Table S1). Furthermore, we did not detect an expanded allele in the mother II.6 with amplification-free targeted sequencing. She carried two normal alleles with 13 and 14 repeats (Table 1). DNA from the father (II.5), who died before the study began, was unavailable.

Table 1. Allele count for normal and expanded *ATXN10* alleles in a Mexican family

Pedigree ID	Disease	Sex	Age at onset	Age at blood collection	Allele 1 count	Allele 1 count range	Allele 2 count	Allele 2 count range	Repeat type
II.6	unaffected	F	N/A	90	38	13–14	none	N/A	normal
III.2 ^a	SCA10	F	35	71	N/A	N/A	N/A	N/A	interrupted
III.3 ^a	SCA10	F	48	68	N/A	N/A	N/A	N/A	interrupted
III.4	unaffected	M	N/A	65	143	13–14	130	4750-7187	pure
III.6 ^a	unaffected	F	N/A	70	N/A	N/A	N/A	N/A	pure
III.7 ^a	SCA10	M	48	65	N/A	N/A	N/A	N/A	interrupted
III.8 ^a	Parkinson's	M	38	57	N/A	N/A	N/A	N/A	pure
III.9 ^a	SCA10	F	37	53	N/A	N/A	N/A	N/A	interrupted
IV.1	SCA10	F	44	44	263	13–14	22	6422-6927	interrupted
IV.4	unaffected	F	51	51	76	15–16	5	6338-6515	interrupted
IV.5	unaffected	F	41	41	193	13–15	59	6244-9318	interrupted
IV.6	unaffected	F	43	43	183	13–15	73	5914-8314	interrupted
IV.7	unaffected	F	N/A	39	271	15–17	49	330-14038	pure
IV.8	unaffected	F	N/A	19	193	16–17	58	2383-7920	pure
IV.9	unaffected	F	N/A	44	297	13–17	419	2730-6502	pure

^aIndividuals previously published in Schüle et al.¹⁵

Our interpretation from these clinical genetic findings is that the father was compound heterozygous for both the pure and the mixed extended allele, although we cannot fully exclude that he carried an unstable interrupted repeat that may have been lost the ATTCT interruption during transmission. However, the interrupted allele presents with a complex structure including dispersed repeats of ATTTCT and ATTCCT (Figure S1), which makes it unlikely that the repeat expansion lost its ATTCC repeat during transmission and expanded the ATTCT repeat in parallel and for several offspring in generation III. In a yeast model system, a proposed mechanism for repeat contractions is template skipping, whereas repeat expansions for ATTCT could be due to a template switch where the nascent leading strand might occasionally switch from its template to the nascent lagging strand.¹⁸ Clinically, the father presented with a typical SCA10 symptom complex based on his medical history, including seizures and no aggravated clinical phenotype or faster progression. He died at the age of 67.

Accurate sizing of *ATXN10* pentanucleotide expansions

Previously, we used amplification-free targeted sequencing to sequence the entire *ATXN10* repeat expansion and detected expansions between 1,076 and 1,363 pentanucleotide repeat expansions (5,380 to 6,815 bp) in generation III of this family.¹⁵ Long-read amplification-free targeted sequencing allows for accurate sizing in repeat composition by sequencing through the entire *ATXN10* repeat without prior DNA template amplification. While we had confidence that the repeat length was correct, as the Cas9/small guide RNA recognition site is upstream of the repeat expansion, it was in stark contrast to the diagnostic sizing with PCR/southern

blotting by Athena Diagnostics. The proband III.8 with Parkinson's disease presented 1,304 repeats (6,520 bp) for the expanded allele with PacBio amplification-free targeted sequencing. In contrast, diagnostic testing using Athena Diagnostics (test code 6901, PCR, southern blot) resulted in 1,968 ATTCT repeats (9,840 bp) for the extended allele, a size difference of 664 repeats (3,320 bp). Similarly, the affected brother III.7 presented 1,363 repeats (6,815 bp) with PacBio and 2,223 ATTCT repeats of the extended allele (11,115 bp) with Athena Diagnostics, a size difference of 860 repeats (4,300 bp).

It is known that Southern blotting can result in variable sizing between different diagnostic labs; hence, we wanted to address the repeat sizing with another independent technique using an amplification-free strategy. We decided to perform optical genome mapping using high-density nanochannel arrays and imaging on a Saphyr instrument (Bionano Genomics) that allows detection of structural variants greater than 500 bp. Optical genome-mapping images of long amplification-free DNA molecules fluorescently labeled at specific 6–7 bp sites preserve all genomic structural information. Optical genome mapping detects structural variants down to 1% variant allele fraction for mosaic samples.

We collected new blood samples from four family members with known repeat expansions previously detected with no-amp targeted sequencing. All four samples with an extended allele were correctly categorized as an insertion in intron 9 of the *ATXN10* gene with coordinates chr22:46,191,235–46,191,304 (Hg38). Per sample, we resolved between 66 and 144 molecules (expanded alleles between 33 and 54) (Table S2). The repeat expansion sizes

were comparable between the amplification-free targeted sequencing and optical genome mapping and show similar sizing and variability.

Somatic mosaicism detected with both no-amp targeted sequencing and optical genome mapping

Next, we compared the size range of the expanded allele for PacBio amplification-free targeted sequencing and optical genome mapping. For amplification-free targeted sequencing, we sequenced, on average, 101 CCS reads for the expanded allele (range: 5–419 CCS reads). Interestingly, we found that samples with a mixed repeat show less variability in the size of the expanded allele (average of 1,539 bp; range: 177–3,074 bp) compared with the pure repeat expansion (average of 6,363 bp; range: 2,437–13,708 bp). These data indicate that the pure expansions might be less stable and exhibit more somatic variability than the mixed *ATXN10* repeat expansions.

For Bionano optical genome mapping, we had two samples with a pure repeat expansion for direct comparison. While optical genome mapping cannot give precise estimates down to individual bp resolution, we estimated the consensus map size and subtracted the size (5,355 bp) between the consensus map labels to report the repeat expansion size. Both samples III.4 and III.6 showed similar repeat expansion lengths and levels of somatic variability (Figure 4N, violin plots), whereas IV.7 showed a high degree of somatic mosaicism with unstable expanded repeats (Figures 2 and 3), which we further evaluated in skin fibroblasts from these individuals (Figure 4).

Variable *ATXN10* repeat sizes correlate with varying counts of *ATXN10* RNA foci in patient-derived skin fibroblasts

To investigate to what extent the somatic variability of the *ATXN10* repeat size relates to (ATTCT)_n repeat RNA foci within cells, we custom-designed an *in situ* hybridization RNAScope probe against the ATTCT repeat. It is known that spliced intronic repeat expansions can accumulate as intracellular RNA foci and contribute to cellular stress and neurodegeneration.¹⁹

We derived skin fibroblasts from three individuals with *ATXN10* repeat expansions (III.4, III.6, and IV.7) and one healthy relative (IV.2) who had two normal *ATXN10* alleles. We detected RNA foci within the nuclei and cytoplasm in all individuals with the expanded *ATXN10* allele and none in the control (Figures 4E–4L). Positive and negative RNAScope controls were included (Figures 4A–4D). When we quantified the number of RNA aggregates in the three individuals with the expanded *ATXN10* allele, we counted an average of 3.51 and 2.33 foci in cases III.4 and III.6 and 26.65 in case IV.7, with a wide range of counts that correlated to the amplification-free targeted sequencing data and the *ATXN10* repeat sizing of the optical genome mapping (Table 1; Figure 4M).

Discussion

Three factors of the repeat expansion might influence clinical presentation and outcome: repeat length, repeat interruption, and somatic mosaicism.^{20,21}

While it is known that the pathogenic repeat length for the *ATXN10* repeat expansion is >850 repeats, there are significant gaps in our current knowledge about the nature and clinical relevance of repeat composition and repeat interruptions. Advanced long-read sequencing technologies and optical genome mapping allow us now to fully resolve very large repeat expansions.

Somatic mosaicism of (ATTCT)_n and (ATTCT)_n(ATTCC)_n repeat expansions

The advantage of amplification-free targeted sequencing and optical genome mapping is that these techniques directly use genomic DNA without introducing amplification errors, recombination effects, or cell culture artifacts through prior amplification.

On the one hand, we found that repeat interruptions, as in the mixed (ATTCT)_n(ATTCC)_n repeat expansions, can stabilize the repeat as been previously reported (Figure 2).²² On the other hand, the individuals with the pure (ATTCT)_n expansion show more variability in the size of the expanded alleles (average of 6,363 bp; range: 2,437–13,708 bp) compared with the mixed repeat expansion alleles (average of 1,539 bp; range: 177–3,074 bp). In particular, we identified one individual (IV.7) with a very unstable (ATTCT)_n allele ranging from 66 to 2,782 (ATTCT)_n repeats. This variability is present with PacBio amplification-free targeted sequencing and Bionano optical genome mapping (Figures 2 and 3).

This unstable repeat expansion also translates into variable counts of intracellular inclusions or RNA foci in primary skin fibroblasts from these cases. However, we do not know if and how these RNA foci translate to cellular stress, degeneration, and the development of clinical symptoms. Still, it has been shown that specific RNA-binding proteins get sequestered by the repeat expansion with particular sequence motifs, e.g., heterogeneous nuclear ribonucleoprotein K binds to the ATTCT repeat.²³

Reduced disease penetrance in individuals with pure ATTCT expansions

In this Mexican kindred, we identified two distinct *ATXN10* repeat expansions. One expansion was a pure (ATTCT)_n expansion with no interruptions and a repeat length between 1,278 and 2,782 repeats (Figure S1). The second repeat is a mixed repeat with (ATTCT)_n(ATTCC)_n clinically associated with SCA10, whereas the pure repeat expansion shows reduced penetrance for SCA10.

Of the six individuals with pure *ATXN10* repeat expansions, none showed clinical signs that would allow for the diagnosis of SCA10. However, as we reported earlier, one relative presented with Parkinson's disease.¹⁵ While




Figure 4. RNAScope *in situ* hybridization of *ATXN10* repeat expansion

(A and B) RNAScope human mRNA positive control.

(C and D) RNAScope human negative control.

(E and F) Healthy control.

(G and H) Individual with *ATXN10* repeat expansion III.6.

(I and J) Individual with *ATXN10* repeat expansion III.4.

(K and L) Individual with *ATXN10* repeat expansion IV.7.

(E, G, I, and K) Hs-*ATXN10*-ATTCT-C1 RNAScope probe. (B, D, F, H, J, and L) Merge with DAPI. Scale bar in (B) represents 20 μ m and applies to all images.

(M) Violin plots of counts of RNA foci per cell using ImageXpress. Mean number of RNA signals per cells for control = 0.29, standard deviation (SD) 0.6 (1,870 nuclei); III.6 = 3.51, SD 2.33 (2,034 nuclei); III.4 = 3.89, SD 2.70 (759 nuclei); IV.7 = 26.65, SD 11.71 (2,034 nuclei).

(N) Violin plots for Bionano Saphyr optical genome mapping structural variant calls of the *ATXN10* repeat expansion region for the same individual with *ATXN10* repeat expansion (bp, base pairs). Normal allele size for control = 5,355 bp (normal allele); median expanded allele size III.6 = 5,459 bp (\pm 1,091 ATTCT repeats); III.4 = 6,260 bp (\pm 1,252 ATTCT repeats); IV.7 = 13,102 bp (\pm 2,620 ATTCT repeats). p values are represented as *p = 0.001 and ****p = 0.0001.

three individuals with expansions might be pre-symptomatic (at ages 18, 38, and 44 years), two relatives from the third generation were 65 and 70 years at the time of assessment. They did not show clinical signs of SCA10 (assessed by F.J.J.G. and A.C.-P.; clinical examination III.6 in the [supplemental information](#)).

Notably, the seven siblings tested in generation III carry either a pure or a mixed repeat expansion, and the mother

II.6 did not carry any *ATXN10* expansion, suggesting that their father II.5 was compound heterozygous for the pure and mixed *ATXN10* repeat expansion. By history, he had the typical presentation of SCA10 and died at age 67.

Both results suggest that the pure originally described (ATTCT)_n expansion is not pathogenic, whereas repeat insertions or interruptions cause SCA10 symptoms. The ability to sequence through the entire repeat expansion from

genomic DNA with long-read sequencing techniques makes it possible to resolve the complete sequence of the *ATXN10* repeat expansion—a feat not possible using Southern blot analysis, PCR electrophoresis, or repeat-prime PCR.¹³

Characterizations of *ATXN10* expansions in additional SCA10 families, using the methodology presented in this paper, are needed to better understand if (1) all SCA10 individuals have ATTCC interruptions, (2) large pure ATTCT repeat expansions are present in the unaffected population, or (3) other genetic/epigenetic modifiers may prevent SCA10 clinical presentation.

Our results indicate that *ATXN10* repeat expansions fall into a category of repeat expansions that only become clinically symptomatic when repeat interruptions are present. Similar genetic loci have recently been reported for spinocerebellar ataxia 31 (SCA31 [MIM:117210]),²⁴ spinocerebellar ataxia 37 (SCA37 [MIM:615945]),^{25,26} and three loci for benign adult familial myoclonic epilepsy 1 (BAFME1 [MIM:601068]),²⁷ where repeat interruptions are inserted in non-pathogenic repetitive motifs. In SCA31, which is caused by a complex intronic pentanucleotide repeat that contains (TGGAA)_n, (TAGAA)_n, (TAAAA)_n, and (TAAAATAGAA)_n repeats in the gene called brain expressed, associated with Nedd4 (*BEAN1* [MIM:612051]), only the (TGGAA)_n repeat drives pathogenicity.²⁴ An (ATTTC)_n insertion causes SCA37 within a polymorphic ATTTT repeat in the non-coding 5′ untranslated region of the *DAB adapter protein 1* gene (*DAB1* [MIM:603448]).^{25,26} Lastly, BAFME1 is caused by intronic (TTTCA)_n and (TTTTA)_n repeats in the sterile α-motif domain-containing protein 12 gene (*SAMD12* [MIM:618073]), the trinucleotide repeat-containing gene 6A (*TNRC6A* [MIM:610739]), and the Rap guanine nucleotide-exchange factor 2 gene (*RAPGEF2* [MIM:609530]), where the same repeat (TTTCA)_n and (TTTTA)_n is driving pathogenicity regardless of the locus or gene in which the repeats are located.²⁷

We propose that the pure (ATTCT)_n is non-pathogenic or has only low penetrance with a mild disease course. In contrast, repeat interruptions mainly drive the clinical symptoms and presumably neuropathology. Longitudinal follow-up and *in vitro* functional studies will be essential to understand the *ATXN10* repeat expansion pathophysiology further. Mechanistically, the insertion of repeats into the (ATTCT)_n might be a driving factor for disease causation in SCA10 by sequestering certain RNA-binding proteins that do not bind to the (ATTCT)_n repeat.

In summary, amplification-free targeted sequencing technology and optical genome mapping allow for accurate sizing of the repeat expansion and composition and can reveal somatic mosaicism, which is impossible with current diagnostic methods. While repeat-prime PCR is available at a lower cost and can delineate some of the genomic structure, it cannot resolve the complete length of the repeat expansion and can only detect known repeat motifs with pre-designed primers.¹³ We developed a 15-gene multiplex panel

to detect repeat expansion disorders using no-amp targeted sequencing,²⁸ which could serve as a platform technology for clinical diagnostics.

Deciphering the composition of repeat expansion will allow us to distinguish between pathogenic and non-pathogenic repeats, unravel disease mechanisms, and develop targeted therapies. These advanced genetic technologies are critical not only for implementing better diagnostic testing to diagnose disease more precisely but also for facilitating accurate genetic counseling as variation in the repeat can affect disease penetrance, symptoms, and disease trajectory.

Data and code availability

The Bionano data from five samples (III.4, III.6, III.9, IV.7, and IV.10) generated during this study are available at the NCBI BioProject database under BioProject: PRJNA838989 (<https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA838989>).

Supplemental information

Supplemental information can be found online at <https://doi.org/10.1016/j.xhgg.2022.100137>.

Acknowledgments

We are indebted to the family members for their participation in this study and their commitment to helping the understanding of underlying genetic causes of neurodegenerative disorders. We thank Jose Miranda for supporting study recruitment. Start-up funding and Chan Zuckerberg Initiative Supplement funds to B.S. supported the research. We received in-kind donations from PacBio and Bionano in the form of sequencing and optical genome mapping.

Declaration of interests

I.M., Y.-C.T., and J.Z. are employees and shareholders of Pacific Biosciences. K.H., J. Lai, J. Lee, and M.D.G. are employees and shareholders of Bionano Genomics. B.S., F.J.J.G., J.P.V., F.Z., C.A.M.T., F.T., T.A., J.F.-R., A.C.-P., and A.O.R.-M. declare no competing interests.

Received: May 11, 2022

Accepted: August 11, 2022

Web resources

Online Mendelian Inheritance in Man, <http://www.omim.org>.

References

1. Rodríguez-Labrada, R., Martins, A.C., Magaña, J.J., Vazquez-Mojena, Y., Medrano-Montero, J., Fernandez-Ruiz, J., Cisneros, B., Teive, H., McFarland, K.N., Saraiva-Pereira, M.L., et al. (2020). Founder effects of spinocerebellar ataxias in the American continents and the caribbean. *Cerebellum* 19, 446–458.

2. Matsuura, T., Yamagata, T., Burgess, D.L., Rasmussen, A., Grewal, R.P., Watase, K., Khajavi, M., McCall, A.E., Davis, C.F., Zu, L., et al. (2000). Large expansion of the ATTCT pentanucleotide repeat in spinocerebellar ataxia type 10. *Nat. Genet.* *26*, 191–194.
3. McFarland, K.N., Liu, J., Landrian, I., Godiska, R., Shanker, S., Yu, F., Farmerie, W.G., and Ashizawa, T. (2015). SMRT sequencing of long tandem nucleotide repeats in SCA10 reveals unique insight of repeat expansion structure. *PLoS One* *10*, e0135906.
4. Moro, A., Munhoz, R.P., Moscovich, M., Arruda, W.O., Raskin, S., Silveira-Moriyama, L., Ashizawa, T., and Teive, H.A.G. (2017). Nonmotor symptoms in patients with spinocerebellar ataxia type 10. *Cerebellum* *16*, 938–944.
5. Santos, L.R., Teive, H.A.G., Lopes Neto, F.D.N., Macedo, A.C.B.d., Mello, N.M.d., and Zonta, M.B. (2018). Quality of life in individuals with spinocerebellar ataxia type 10: a preliminary study. *Arq. Neuropsiquiatr.* *76*, 527–533.
6. Moro, A., Munhoz, R.P., Camargo, C.H., Moscovich, M., Farah, M., and Teive, H.A.G. (2020). Is fatigue an important finding in patients with spinocerebellar ataxia type 10 (SCA10)? *J. Clin. Neurosci.* *71*, 150–152.
7. London, E., Camargo, C.H.F., Zanatta, A., Crippa, A.C., Raskin, S., Munhoz, R.P., Ashizawa, T., and Teive, H.A.G. (2018). Sleep disorders in SCA10. *J. Sleep Res.* *27*, e12688.
8. Moscovich, M., Munhoz, R.P., Moro, A., Raskin, S., McFarland, K., Ashizawa, T., Teive, H.A.G., and Silveira-Moriyama, L. (2019). Olfactory function in SCA10. *Cerebellum* *18*, 85–90.
9. Schultz, D.B., Nascimento, F.A., Camargo, C.H.F., Ashizawa, T., and Teive, H.A.G. (2020). Cancer frequency in patients with SCA10. *Parkinsonism Relat. Disord.* *76*, 1–2.
10. Hernandez-Castillo, C.R., Diaz, R., Vaca-Palomares, I., Torres, D.L., Chirino, A., Campos-Romo, A., Ochoa, A., Rasmussen, A., and Fernandez-Ruiz, J. (2019). Extensive cerebellar and thalamic degeneration in spinocerebellar ataxia type 10. *Parkinsonism Relat. Disord.* *66*, 182–188.
11. Bastepe, M., and Xin, W. (2015). Huntington disease: molecular diagnostics approach. *Curr. Protoc. Hum. Genet.* *87*, 9.26.1–9.26.23.
12. Viguera, E., Canceill, D., and Ehrlich, S.D. (2001). In vitro replication slippage by DNA polymerases from thermophilic organisms. *J. Mol. Biol.* *312*, 323–333.
13. Hashem, V., Tiwari, A., Bewick, B., Teive, H.A.G., Moscovich, M., Schüle, B., Bushara, K., Bower, M., Rasmussen, A., Tsai, Y.C., et al. (2020). Pulse-Field capillary electrophoresis of repeat-primed PCR amplicons for analysis of large repeats in Spinocerebellar Ataxia Type 10. *PLoS One* *15*, e0228789.
14. McFarland, K.N., Liu, J., Landrian, I., Zeng, D., Raskin, S., Moscovich, M., Gatto, E.M., Ochoa, A., Teive, H.A.G., Rasmussen, A., and Ashizawa, T. (2014). Repeat interruptions in spinocerebellar ataxia type 10 expansions are strongly associated with epileptic seizures. *Neurogenetics* *15*, 59–64.
15. Schüle, B., McFarland, K.N., Lee, K., Tsai, Y.C., Nguyen, K.D., Sun, C., Liu, M., Byrne, C., Gopi, R., Huang, N., et al. (2017). Parkinson's disease associated with pure ATXN10 repeat expansion. *NPJ Parkinsons Dis.* *3*, 27.
16. Tsai, Y.-C., Greenberg, D., Powell, J., Höijer, I., Ameer, A., Strahl, M., Ellis, E., Jonasson, I., Mouro Pinto, R., Wheeler, V.C., et al. (2017). Amplification-free, CRISPR-Cas9 targeted enrichment and SMRT sequencing of repeat-expansion disease causative genomic regions. Preprint at bioRxiv.
17. Vangipuram, M., Ting, D., Kim, S., Diaz, R., and Schüle, B. (2013). Skin punch biopsy explant culture for derivation of primary human fibroblasts. *J. Vis. Exp.*, e3779.
18. Cherng, N., Shishkin, A.A., Schlager, L.I., Tuck, R.H., Sloan, L., Matera, R., Sarkar, P.S., Ashizawa, T., Freudenreich, C.H., and Mirkin, S.M. (2011). Expansions, contractions, and fragility of the spinocerebellar ataxia type 10 pentanucleotide repeat in yeast. *Proc. Natl. Acad. Sci. USA* *108*, 2843–2848.
19. Zhang, N., and Ashizawa, T. (2017). RNA toxicity and foci formation in microsatellite expansion diseases. *Curr. Opin. Genet. Dev.* *44*, 17–29.
20. Mangin, A., de Pontual, L., Tsai, Y.C., Monteil, L., Nizon, M., Boisseau, P., Mercier, S., Ziegler, J., Harting, J., Heiner, C., et al. (2021). Robust detection of somatic mosaicism and repeat interruptions by long-read targeted sequencing in myotonic dystrophy type 1. *Int. J. Mol. Sci.* *22*, 2616.
21. Depienne, C., and Mandel, J.-L. (2021). 30 years of repeat expansion disorders: what have we learned and what are the remaining challenges? *Am. J. Hum. Genet.* *108*, 764–785.
22. Villate, O., Ibarluzea, N., Maortua, H., de la Hoz, A.B., Rodriguez-Revenga, L., Izquierdo-Álvarez, S., and Tejada, M.I. (2020). Effect of AGG interruptions on FMR1 maternal transmissions. *Front. Mol. Biosci.* *7*, 135.
23. White, M.C., Gao, R., Xu, W., Mandal, S.M., Lim, J.G., Hazra, T.K., Wakamiya, M., Edwards, S.F., Raskin, S., Teive, H.A.G., et al. (2010). Inactivation of hnRNP K by expanded intronic AUUCU repeat induces apoptosis via translocation of PKCdelta to mitochondria in spinocerebellar ataxia 10. *PLoS Genet.* *6*, e1000984.
24. Ishikawa, K., and Nagai, Y. (2019). Molecular mechanisms and future Therapeutics for spinocerebellar ataxia type 31 (SCA31). *Neurotherapeutics* *16*, 1106–1114.
25. Seixas, A.I., Loureiro, J.R., Costa, C., Ordóñez-Ugalde, A., Marcelino, H., Oliveira, C.L., Loureiro, J.L., Dhingra, A., Brandão, E., Cruz, V.T., et al. (2017). A pentanucleotide AT TTC repeat insertion in the non-coding region of DAB1, mapping to SCA37, causes spinocerebellar ataxia. *Am. J. Hum. Genet.* *101*, 87–103.
26. Loureiro, J.R., Oliveira, C.L., Mota, C., Castro, A.F., Costa, C., Loureiro, J.L., Coutinho, P., Martins, S., Sequeiros, J., and Silveira, I. (2019). Mutational mechanism for DAB1 (AT TTC)n insertion in SCA37: AT TTTT repeat lengthening and nucleotide substitution. *Hum. Mutat.* *40*, 404–412.
27. Ishiura, H., Doi, K., Mitsui, J., Yoshimura, J., Matsukawa, M.K., Fujiyama, A., Toyoshima, Y., Kakita, A., Takahashi, H., Suzuki, Y., et al. (2018). Expansions of intronic TTTCA and TTTTA repeats in benign adult familial myoclonic epilepsy. *Nat. Genet.* *50*, 581–590.
28. Tsai, Y.-C., Zafar, F., McEachin, Z.T., McLaughlin, I.J., Van Blitterswijk, M., Ziegler, J., and Schüle, B. (2022). Multiplex CRISPR/Cas9-Guided No-Amp targeted sequencing panel for spinocerebellar ataxia repeat expansions. In *Genomic Structural Variants in Nervous System Disorders*, C. Proukakis, ed. (Springer US), pp. 95–120.

HGGA, Volume 3

Supplemental information

**ATTCT and ATTCC repeat expansions
in the ATXN10 gene affect disease penetrance
of spinocerebellar ataxia type 10**

C. Alejandra Morato Torres, Faria Zafar, Yu-Chih Tsai, Jocelyn Palafox Vazquez, Michael D. Gallagher, Ian McLaughlin, Karl Hong, Jill Lai, Joyce Lee, Amanda Chirino-Perez, Angel Omar Romero-Molina, Francisco Torres, Juan Fernandez-Ruiz, Tetsuo Ashizawa, Janet Ziegler, Francisco Javier Jiménez Gil, and Birgitt Schüle

Table of Contents

Case Report.....	2
Supplemental Table 1. AmpFISTR™ Identifiler™ testing.....	3
Supplemental Table 2. Summary statistics and QC for optical mapping for de novo assembly pipeline.....	4
Supplemental Figure 1.....	5

Case Report.

III.6. Medical history. At the time of the visit, this 68-year-old female does not report motor symptoms related to cerebellar ataxia. Her everyday living is not precluded by sensorimotor impairments, although she had sciatica pain detected and treated with physical therapy 5 months ago. She clearly identifies the uncoordinated movements, speech difficulties, and seizures experienced by their relatives, but she denies being affected by any of these symptoms. Two years ago, she presented bereavement-related depression accompanied by sadness, irritable mood, and somatic changes, but she responded favorably to antidepressant treatment (fluoxetine), which was discontinued two months ago. Currently, she is not taking any medication other than Losartan and dietary supplements.

Clinical evaluation. The Spanish version of the Center for Epidemiologic Studies Depression Scale (CES-D) showed a score of 0, without the presence of depressive features. The MoCA (Montreal Cognitive Assessment) score revealed normal cognitive performance (28/30, with an extra point for education less than 12 years). In the Cerebellar Cognitive Affective/Schmahmann Syndrome (CCAS) Scale, she had a score of 81/120, failing in categories switching, digit span forward, and similarities. This performance is considered a diagnosis of definite CCAS (normal cut-off ≥ 92 ^{1;2}). Her total SARA (Scale for assessment and rating of ataxia) rating score was 2/40 points because she was not able to perform tandem walking for more than 10 steps. The rest of the tests had a score of 0 (not affected); however, there were subtle changes that were not penalized in the final score. For example, during the first two trials of the finger chase test, she presented hypermetric movements with the right index finger, but the average performance of the last 3 movements was not impaired. In addition, she was able to perform tandem stance for more than 10 seconds during the second trial, but the first trial was affected by postural sway.

References.

1. Chirino-Pérez, A., Marrufo-Meléndez, O.R., Muñoz-López, J.I., Hernandez-Castillo, C.R., Ramirez-Garcia, G., Díaz, R., Nuñez-Orozco, L., and Fernandez-Ruiz, J. (2022). Mapping the Cerebellar Cognitive Affective Syndrome in Patients with Chronic Cerebellar Strokes. *Cerebellum* 21, 208-218.
2. Hoche, F., Guell, X., Vangel, M.G., Sherman, J.C., and Schmahmann, J.D. (2018). The cerebellar cognitive affective/Schmahmann syndrome scale. *Brain* 141, 248-270.

Supplemental Table 1. AmpFISTR™ Identifiler™ testing


Pedigree IDs	FAM								VIC									
	D8S1179		D21S11		D7S820		CSF1PO		D3S1358		TH01		D13S317		D16S539		D2S1338	
II.5 (inferred)	151	142	214	221	275		326	330	129		187	176	225		272	279	329	337
II.6	142	159	206	221	271	275	330		129	143	176	180	229	238	279	279	316	316
III.2	142	151	206	214	275	275	330	330	129	143	180	187			272	279	316	337
III.4	142	142	221	221	271	275	326	330	129	129	176	187	225	238	272	279	316	337
III.6	151	159	206	221	275	275	330	330	129	143	180	187			272	279	316	337
III.7	142	159	206	214	271	275	330	330	129	143	180	187	225	229	279	279	316	329
III.8	151	159	214	220.9	275	275	330	330	129	143	176	180	225	229	272	279	316	329
III.9	142	159	206	221	271	275	330	330	129	129	176	176	225	229	272	279	316	337

Pedigree IDs	NED								PET					
	D19S33		vWA		TPOX		D18S51		Amelogenin (X/Y)		D5S818		FGA	
II.5 (inferred)	123	121	180	188	234	242	306	298		113	139	153	241	245
II.6	121	129	176	180	234	234	286	294	108		153	153	237	254
III.2	121	123	176	180	234	234	286	298	108		139	153	241	254
III.4	121	121	176	188	234	234	294	298	108	113	139	153	237	245
III.6	123	129	176	188	234	234	294	298	108		139	153	241	254
III.7	121	123	176	188	234	234	286	298	108	113	139	153	245	254
III.8	121	121	176	188	234	242	294	306	108	113	139	153	237	245
III.9	121	129	180	188	234	242	286	298	108		153	153	237	241

Supplemental Table 2. Summary statistics and QC for optical mapping for de novo assembly pipeline.

Sample	III.9	III.6	IV.10	III.4	IV.7
Data collected (molecules >150kbp)	1,314.1 Gbp	1,327.86 Gbp	1,336.59 Gbp	1,325.12 Gbp	1,348.2 Gbp
Molecule N50	279.75 kbp	300.38 kbp	269.25 kbp	251.25 kbp	308.63 kbp
Diploid genome map length	6,036.48 Mbp	6,067.1 Mbp	6,003.15 Mbp	6,095.06 Mbp	6,009.44 Mbp
Diploid genome map N50	80.4 kbp	59.72 kbp	69.69 kbp	70.44 kbp	73.6 kbp
Total <i>ATXN10</i> allele counts	66	132	122	111	144
Expanded allele counts	33	54	0	51	48
<i>de novo assembly pipeline SV calls against hg38</i>					
Insertions	2813	2853	2876	2862	2904
Deletions	1313	1286	1275	1269	1255
Inversion breakpoints	53	59	49	64	58
Duplications	76	82	78	86	72
Translocations	7	9	10	6	8

Supplemental Figure 1.



Supplemental Figure 1. *ATXN10* repeat expansion sequence schematics based on No Amp sequencing. Repeat expansions are represented in the 5' (upper left) to 3' (lower right) direction. The schematics and expansion size given are based on the most error-free read length for each sample. Each rectangle represents a sequence motif as follows: white, ATTCT; aqua, ATTCC; gold, ATTCT; purple, ATTCCT. Black rectangles denote miscellaneous motifs that may represent errors in sequence reads.